Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS's Early Oncology Head On Novel IO Approaches & Disruptions

Executive Summary

BMS's early oncology chief Tim Reilly says the company's sprawling immuno-oncology pipeline might look "haphazard," but there is beauty in the bedlam.

You may also be interested in...



Roche Pushes The Boundaries Of Cancer Immunotherapy

Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.

IDO Updates At ASCO: Incyte's Combos With Merck And Bristol Take Center Stage

The immuno-oncology highlight of the upcoming American Society of Clinical Oncology annual meeting will be clinical data for Incyte's epacadostat with Merck's Keytruda as well as data with Bristol's Opdivo.

Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration

Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel